GlassScriptPhysician profile
Steven M Geller
NPI 1194836387
$274,453.34
in general payments reported to CMS, 2019-2025
48 companies · $38K in 2025
The $38K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,787 · 2020: $17K · 2021: $35K · 2022: $45K · 2023: $68K · 2024: $67K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150K · Food and Beverage: $16K · Travel and Lodging: $3,654 · Consulting Fee: $3,255 · Education: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150,383.80 |
| Food and Beverage | $15,883.89 |
| Travel and Lodging | $3,653.56 |
| Consulting Fee | $3,255.00 |
| Education | $549.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $140,793.89 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $99,197.54 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Regeneron Healthcare Solutions, INC. | $16,323.34 | 2019-2025 | Dupixent |
| Amgen INC. | $4,312.71 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,691.35 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| United Therapeutics Corporation | $1,196.37 | 2019-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $1,161.69 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $1,137.77 | 2019-2025 | |
| Mylan Specialty L.P. | $1,102.43 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $903.27 | 2019-2025 | Uptravi, Opsumit |
| Harmony Biosciences LLC | $699.44 | 2021-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $681.77 | 2020-2025 | Aralast, Glassia |
| Insmed, INC. | $664.98 | 2019-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $575.97 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Grifols USA, LLC | $444.68 | 2019-2025 | Prolastin-C Liquid |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.